CD44 and breast carcinoma: Flow cytometry analysis revealed a decrease in the breast cancer stem cell population (CD44+CD24‐) in MDA‐MB‐231 cells from 95.5% to 76.5%, while in BT‐549 cells, the percentage remained nearly constant (62.1%–61.2%) (Figure 6C).